help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Published ahead of print on September 5, 2008, doi:10.1164/rccm.200804-494OC

Am. J. Respir. Crit. Care Med., Volume 178, Number 10, November 2008, 1009-1016

A more recent version of this article appeared on November 15, 2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200804-494OCv1
178/10/1009    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jaeschke, R.
Right arrow Articles by Guyatt, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jaeschke, R.
Right arrow Articles by Guyatt, G.

Submitted on April 1, 2008
Accepted on September 5, 2008

The Safety of Long Acting Beta Agonists Among Patients with Asthma Using Inhaled Corticosteroids

Roman Jaeschke1*, Paul M O'Byrne2, Filip Mejza3, Parameswaran Nair2, Wiktoria Lesniak3, Jan Brozek4, Lehana Thabane5, Ji Cheng6, Holger J Schunemann7, Malcom R Sears2, and Gordon Guyatt8

1 Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Polish Institute of EBM, Krakow, Poland, 2 Department of Medicine, McMaster University, Hamilton, Ontario, Canada, 3 Polish Institute of EBM, Krakow, Poland; II Katedra Chorob Wewnetrznych, Jagiellonian University School of Medicine, Krakow, Poland, 4 Polish Institute of EBM, Krakow, Poland; II Katedra Chorob Wewnetrznych, Jagiellonian University School of Medicine, Krakow, Poland; Italian National Cancer Institute, Rome, Italy, 5 Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; Biostatistics Unit, Father Sean O'Sullivan Research Centre, St Joseph's Healthcare, Hamilton, Ontario, Canada, 6 Biostatistics Unit, Father Sean O'Sullivan Research Centre, St Joseph's Healthcare, Hamilton, Ontario, Canada, 7 Italian National Cancer Institute, Rome, Italy; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; CLARITY Research Group in the Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada, 8 Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; CLARITY Research Group in the Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada

* To whom correspondence should be addressed. E-mail: Jaeschke{at}mcmaster.ca.

Background: Inhaled long acting beta agonists (LABAs) when used as monotherapy in asthma may increase asthma-related hospitalizations, life threatening events requiring intubation/mechanical ventilation and asthma-related deaths, but concomitant use of inhaled corticosteroids (ICS) may modify this effect. Methods: We conducted a systematic review and meta-analysis of parallel group, blinded, randomized controlled trials with at least 12 weeks of treatment addressing the impact of LABA on asthma-related and total morbidity and mortality in patients concomitantly using ICS. We searched MEDLINE, EMBASE, ACPJC, and Cochrane (Central) databases and contacted authors and sponsors. We used random effects model to pool results from different studies as odds ratio [OR] (95% confidence interval) (OR < 1.0 favors LABA). Findings: The search yielded 62 relevant studies included in this analysis. Among over 29,000 participants (15,710 taking LABA with over 8,000 patient-years observation in LABA groups) there were 3 asthma-related deaths and 2 asthma-related non-fatal intubations (all in LABA groups, no more than one event per study). Differences in asthma-related hospitalizations (OR 0.74, 95% CI 0.53 - 1.03) and asthma-related serious adverse events (mostly hospitalizations, OR 0.75, 95% CI 0.54 - 1.03) failed to reach statistical significance. The OR for total mortality was 1.26, 95% CI 0.58 - 2.74 reflecting 14 deaths in LABA groups and 8 deaths in control groups respectively. Interpretation: In patients with asthma using inhaled corticosteroids LABA did not increase the risk of asthma-related hospitalizations. There were very few asthma-related deaths and intubations, and events were too infrequent to establish LABA's relative effect on these outcomes.
Key words: long-acting beta agonists, randomized trials, toxicity, adverse events, systematic review




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. Adner, B. Larsson, J. Safholm, I. Naya, and A. Miller-Larsson
Budesonide Prevents Cytokine-Induced Decrease of the Relaxant Responses to Formoterol and Terbutaline, but Not to Salmeterol, in Mouse Trachea
J. Pharmacol. Exp. Ther., April 1, 2010; 333(1): 273 - 280.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
X. Sun, M. Briel, S. D. Walter, and G. H. Guyatt
Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses
BMJ, March 30, 2010; 340(mar30_3): c117 - c117.
[Full Text]

Home page
 cfpHome page
A. D. D'Urzo, P. Jugovic, J. Bouchard, R. Jhirad, and I. Tamari
Safety of long-acting {beta}2-agonists in the management of asthma: A Primary Care Respiratory Alliance of Canada perspective
Can Fam Physician, February 1, 2010; 56(2): 119 - 120.
[Full Text] [PDF]

Home page
 cfpHome page
A. D. D'Urzo, P. Jugovic, J. Bouchard, R. Jhirad, and I. Tamari
Innocuite des {beta}2-agonistes dans la prise en charge de l'asthme: Un point de vue de la Primary Care Respiratory Alliance of Canada
Can Fam Physician, February 1, 2010; 56(2): 123 - 124.
[Full Text] [PDF]

Home page
 ACCP/AAP Ped Pul Brd RevHome page
L. Hendeles
Pharmacology Review
ACCP AAP Ped Pul Brd Rev, January 1, 2010; 1(0): 243 - 248.
[Extract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. Beasley, M. Wijesinghe, and M. Weatherall
Potential Risks of Using LABAs with ICS Therapy
Am. J. Respir. Crit. Care Med., September 15, 2009; 180(6): 581 - 581.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. Jaeschke, P. Nair, L. Thabane, and J. Brozek
Potential Risks of Using LABAs with ICS Therapy
Am. J. Respir. Crit. Care Med., September 15, 2009; 180(6): 581 - 582.
[Full Text] [PDF]

Home page
 ChestHome page
M. R. Sears
Safety of Long-Acting {beta}-Agonists: Are New Data Really Required?
Chest, August 1, 2009; 136(2): 604 - 607.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. Sindi, D. C. Todd, and P. Nair
Antiinflammatory Effects of Long-Acting {beta}2-Agonists in Patients With Asthma: A Systematic Review and Metaanalysis
Chest, July 1, 2009; 136(1): 145 - 154.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. R. Taylor
The {beta}-Agonist Saga and Its Clinical Relevance: On and On It Goes
Am. J. Respir. Crit. Care Med., June 1, 2009; 179(11): 976 - 978.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
W. C. Moore
Update in Asthma 2008
Am. J. Respir. Crit. Care Med., May 15, 2009; 179(10): 869 - 874.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
B. J. Lipworth
Long-Acting {beta}2 Agonists and Inhaled Corticosteroids in Asthma
Am. J. Respir. Crit. Care Med., May 1, 2009; 179(9): 853 - 854.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2008 American Thoracic Society